Prognostic significance of HER3 in patients with malignant solid tumors.

ABSTRACT: Human epidermal growth factor receptor 3 (HER3) is closely involved in tumor progression and is an important target of therapy. To evaluate the prognostic significance of HER3 in malignant solid tumors, we searched the PUBMED, EMBASE and CNKI databases for relevant studies written in English or Chinese up to December 2015. Fifteen studies comprising 2964 patients were identified. The HER3⁺ rate ranged from 9.0-75.1 % in malignant solid tumors: 30.3-75.1 % in breast cancers, 51.1-74.5 % in colorectal cancers, 13.7-59.0 % in gastric cancers, and 54.5-74.4 % in cervical cancers. For patients with a malignant solid tumor, the death risk was higher for those with a HER3⁺ tumor than for those with a HER3^- tumor (HR 1.60, 95% CI: 1.27 - 2.02, P < 0.001). Su

SUBMITTER: Li Q 

PROVIDER: S-EPMC5620162 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature